Status:
TERMINATED
Assessment of Donor Derived Cell Free DNA and Utility in Lung Transplantation
Lead Sponsor:
Pablo Sanchez
Collaborating Sponsors:
CareDx
Conditions:
Lung Transplant Failure and Rejection
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The use of Allosure to identify and quantify circulating donor-derived cell-free DNA to quantitate allograft injury in the early post-transplant period and determine its relationship to allograft fail...
Detailed Description
Single Center Prospective Cohort Study on De-Novo Lung Transplant recipients. AlloSure will be drawn as part of routine blood draws and sent to CareDx for analysis of dd-cfDNA. All data will be collec...
Eligibility Criteria
Inclusion
- Participant is willing and able to give informed consent for participation in the study.
- Male or Female, aged 18 years or above.
- Denovo lung transplant recipient
- Ability to understand written and spoken English
Exclusion
- Previous transplant or multi-organ transplant
- Unable to have blood draw for medical reason
Key Trial Info
Start Date :
June 29 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2023
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04318587
Start Date
June 29 2020
End Date
December 30 2023
Last Update
March 25 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UPMC Presbyterian
Pittsburgh, Pennsylvania, United States, 15213